An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia

Roberts, 2002, Recent insights into the pathogenesis of pre-eclampsia, Placenta, 23, 359, 10.1053/plac.2002.0819

Redman, 1999, Preeclampsia: an excessive maternal inflammatory response to pregnancy, Am J Obstet Gynecol, 180, 499, 10.1016/S0002-9378(99)70239-5

Lim, 1993, Hypertension in pregnancy, Curr Opin Obstet Gynecol, 5, 40, 10.1097/00001703-199302000-00007

Johansen, 1999, Trophoblast deportation in human pregnancy—its relevance for pre-eclampsia, Placenta, 20, 531, 10.1053/plac.1999.0422

Roberts, 1998, Endothelial dysfunction in preeclampsia, Semin Reprod Endocrinol, 16, 5, 10.1055/s-2007-1016248

Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, 649, 10.1172/JCI17189

Koga, 2003, Elevated serum soluble vascular endothelial growth factor receptor 1(sVEGFR-1) levels in women with preeclampsia, J Clin Endocrinol Metab, 88, 2348, 10.1210/jc.2002-021942

Helske, 2001, Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies, Mol Hum Reprod, 7, 205, 10.1093/molehr/7.2.205

Ahmad, 2004, Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia, Circ Res, 95, 884, 10.1161/01.RES.0000147365.86159.f5

Levine, 2004, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, 350, 672, 10.1056/NEJMoa031884

McKeeman, 2004, Soluble vascular endothelial growth factor receptor-1(sFlt-1) is increased throughout gestation in patients who have preeclampsia develop, Am J Obstet Gynecol, 191, 1240, 10.1016/j.ajog.2004.03.004

Chaiworapongsa, 2004, Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award, Am J Obstet Gynecol, 190, 1541, 10.1016/j.ajog.2004.03.043

Ostendorf, 1999, VEGF(165) mediates glomerular endothelial repair, J Clin Invest, 104, 913, 10.1172/JCI6740

Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491

Thadhani, 2004, First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia, J Clin Endocrinol Metab, 89, 770, 10.1210/jc.2003-031244

National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, 2000, Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, Am J Obstet Gynecol, 183, S1, 10.1067/mob.2000.107928

ACOG Committee on Obstetric Practice, 2002, ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia, Int J Gynaecol Obstet, 77, 67, 10.1016/S0020-7292(02)80002-9

Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3-18.

Vuorela, 2000, Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia, Obstet Gynecol, 95, 353